Passage BIO, Inc. (PASG)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch PASG
See up to 3 months of PASG. The 7-day demo opens the 1M and 3M ranges and puts PASG on your watchlist.
Start 7-day demoLatest PASG insider trades
- Lynx1 Capital Management LP - 10% OwnerOpen-market purchase$206K
William Chou - OfficerOpen-market sale
About Passage BIO, Inc. (PASG)
Passage BIO, Inc. files with the SEC under CIK 0001787297 and is classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
PASG Form 4 activity by transaction type, last 90 days
No Form 4 activity for PASG in the last 90 days.
PASG insider transactions (Form 4)
4425 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.0001 par value per share ("Common Stock") | 50,055 | $4.12 footnote F1 | $206K | |
| ||||||
| Dolan Sondhi | Grant or award | Director Stock Option (right to buy) | 10,539 | $0.00 | - | |
| Derrell Porter | Grant or award | Director Stock Option (right to buy) | 10,539 | $0.00 | - | |
| Thomas Richard Kassberg | Grant or award | Director Stock Option (right to buy) | 10,539 | $0.00 | - | |
 Sandip Kapadia | Grant or award | Director Stock Option (right to buy) | 10,539 | $0.00 | - | |
| Maxine Gowen | Grant or award | Director Stock Option (right to buy) | 10,539 | $0.00 | - | |
| Athena Countouriotis | Grant or award | Director Stock Option (right to buy) | 10,539 | $0.00 | - | |
 Kathleen Borthwick - Officer | Grant or award | Employee Stock Option (right to buy) | 15,610 | $0.00 | - | |
| William Chou - Officer | Grant or award | Employee Stock Option (right to buy) | 58,000 | $0.00 | - | |
| William Chou - Officer | Option exercise | Common Stock | 10,000 | - footnote F1 | - | |
| William Chou - Officer | Open-market sale | Common Stock | 4,076 | $18.44 footnote F4 | $75K | |
| William Chou - Officer | Option exercise | Restricted Stock Unit | 10,000 | $0.00 | - | |
| ||||||
| Kathleen Borthwick - Officer | Option exercise | Common Stock | 5,000 | - footnote F1 | - | |
| Kathleen Borthwick - Officer | Open-market sale | Common Stock | 2,062 | $18.44 footnote F4 | $38K | |
| Kathleen Borthwick - Officer | Option exercise | Restricted Stock Unit | 5,000 | $0.00 | - | |
| ||||||
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.0001 par value per share (Common Stock) | 325 | $6.96 | $2K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 19,783 | $6.99 | $138K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 11,900 | $6.99 | $83K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.0001 par value per share (Common Stock) | 13,123 | $5.44 | $71K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 49,302 | $5.74 | $283K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 66,423 | $5.71 | $379K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 231,600 | $0.35 | $81K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 138,800 | $0.33 | $46K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 213,257 | $0.33 | $70K | |
| Thomas Richard Kassberg | Grant or award | Director Stock Option (right to buy) | 143,789 | $0.00 | - | |
| Maxine Gowen | Grant or award | Director Stock Option (right to buy) | 201,857 | $0.00 | - | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 78,049 | $0.34 | $27K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 89,328 | $0.34 | $30K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 68,195 | $0.32 | $22K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 10,326 | $0.38 | $4K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 61,638 | $0.33 | $20K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 77,090 | $0.33 | $25K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.0001 par value per share | 373,645 | $0.65 | $241K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 230,321 | $0.60 | $138K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 54,181 | $0.84 | $46K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 8,015 | $0.80 | $6K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 80 | $0.80 | $64 | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 76,200 | $0.79 | $60K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market sale | Common Stock | 20,903 | $0.82 | $17K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.0001 par value per share ("Common Stock") | 259,998 | $0.56 | $147K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 167,055 | $0.71 | $118K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 29,300 | $0.67 | $20K | |
| Edgar B. Cale - Officer | Grant or award | Employee Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Thomas Richard Kassberg | Grant or award | Employee Stock Option (right to buy) | 174,139 | $0.00 | - | |
Item 1.01, 3.02, 9.01
Item 1.01, 1.02, 3.02, 5.01, 5.02, 7.01, 8.01, 9.01
Item 1.02
Item 5.07
PASG insider trading FAQ
What is the latest insider trade for PASG?
Passage BIO, Inc. (PASG) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-29. The full record for PASG runs to 25 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PASG stock?
No insider purchases of PASG were filed in the last 90 days. 11 purchases are on record for this company.
How many insiders are selling PASG stock?
No insider sales of PASG were filed in the last 90 days. 17 sales are on record for this company.
Where can I see PASG SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PASG Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Lynx1 Capital Management LP view on EDGAR
- - Dolan Sondhi view on EDGAR
- - Derrell Porter view on EDGAR
- - Thomas Richard Kassberg view on EDGAR
- - Sandip Kapadia view on EDGAR
- - Maxine Gowen view on EDGAR
- - Athena Countouriotis view on EDGAR
- - Kathleen Borthwick view on EDGAR
- - William Chou view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where PASG's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PASG with a 7-day demo
- PASG on your watchlist
- Every PASG Form 4 filing on record
- Up to 3 months of PASG price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
